Members and witnesses described after-hours documentation as a major burnout trigger and pointed to usability, interoperability, and workflow fixes that could help.
The House Energy & Commerce Committee zeroed in on concentration, rebates, and pharmacy steering.
A shutdown deal, stalled ACA subsidies, TrumpRx rollout, and growing pressure on states and industry.
Inside a system where bad actors exploit patients, providers, and public trust—often in plain sight.
Clinical trials, vaccines, trust—and why the numbers mattered more than the rhetoric.
As Washington remains partially shut down, vaccine policy, addiction strategy, and drug pricing are all in flux.
Senators pressed FDA gaps, China/India exposure, and a push for origin labels plus QR-linked data.
Lawmakers pressed insurance company executives on premiums, denials, consolidation, and patient harm.
Senate Democrats are blocking the DHS/HHS/Defense funding bill after a Minneapolis shooting, pushing Congress toward a shutdown deadline.
Consolidation took center stage at the House Budget Hearing. From dominant PBMs to hospital market power fueling higher prices, patients' choices are increasingly limited.
The new week opens with must-pass funding, behavioral health uncertainty, and major signals on vaccines and GLP-1s.
Senators clashed over safety evidence, adverse-event reporting, and whether telehealth/mail-order access should be rolled back.
